IO102-103
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for IO102-103, covering 2026-03-03 to 2026-03-03. Get the full timeline:
Most recent: Clinical Trial Update: Neoadjuvant Pembrolizumab and IO102-103 for Squamous Cell Carcinoma of the Head and Neck (SCCHN). [Phase 2]